1. Identification of a 3-Alkylpyridinium Compound from the Red Sea Sponge Amphimedon chloros with In Vitro Inhibitory Activity against the West Nile Virus NS3 Protease.
- Author
-
O'Rourke, Aubrie, Kremb, Stephan, Duggan, Brendan M, Sioud, Salim, Kharbatia, Najeh, Raji, Misjudeen, Emwas, Abdul-Hamid, Gerwick, William H, and Voolstra, Christian R
- Subjects
Hela Cells ,Animals ,Humans ,Porifera ,West Nile virus ,Pyridinium Compounds ,Viral Nonstructural Proteins ,Protease Inhibitors ,Antiviral Agents ,Magnetic Resonance Spectroscopy ,Molecular Structure ,Structure-Activity Relationship ,Models ,Molecular ,Gas Chromatography-Mass Spectrometry ,High-Content Screening ,NS3 protease ,Red Sea ,West Nile Virus ,antiviral ,bioprospecting ,halitoxin ,HeLa Cells ,Medicinal and Biomolecular Chemistry ,Organic Chemistry ,Theoretical and Computational Chemistry - Abstract
Viruses are underrepresented as targets in pharmacological screening efforts, given the difficulties of devising suitable cell-based and biochemical assays. In this study we found that a pre-fractionated organic extract of the Red Sea sponge Amphimedon chloros was able to inhibit the West Nile Virus NS3 protease (WNV NS3). Using liquid chromatography⁻mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy, the identity of the bioactive compound was determined as a 3-alkylpyridinium with m/z = 190.16. Diffusion Ordered Spectroscopy (DOSY) NMR and NMR relaxation rate analysis suggest that the bioactive compound forms oligomers of up to 35 kDa. We observed that at 9.4 μg/mL there was up to 40⁻70% inhibitory activity on WNV NS3 protease in orthogonal biochemical assays for solid phase extracts (SPE) of A. chloros. However, the LC-MS purified fragment was effective at inhibiting the protease up to 95% at an approximate amount of 2 µg/mL with negligible cytotoxicity to HeLa cells based on a High-Content Screening (HCS) cytological profiling strategy. To date, 3-alkylpyridinium type natural products have not been reported to show antiviral activity since the first characterization of halitoxin, or 3-alkylpyridinium, in 1978. This study provides the first account of a 3-alkylpyridinium complex that exhibits a proposed antiviral activity by inhibiting the NS3 protease. We suggest that the here-described compound can be further modified to increase its stability and tested in a cell-based assay to explore its full potential as a potential novel antiviral capable of inhibiting WNV replication.
- Published
- 2018